Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMUJF9T)

Drug Name
CD123-CD33 Ccar Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [1]
Myelodysplastic syndrome 2A37 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMUJF9T

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 3 receptor alpha (IL3RA) TTENHJ0 IL3RA_HUMAN Not Available [2]
Myeloid cell surface antigen CD33 (CD33) TTJVYO3 CD33_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Myeloid cell surface antigen CD33 (CD33) DTT CD33 2.485 2.744 2.868 2.744
Interleukin 3 receptor alpha (IL3RA) DTT IL3RA 1.807 3.926 2.678 3.573
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Acute myeloid leukaemia
ICD Disease Classification 2A60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Myeloid cell surface antigen CD33 (CD33) DTT CD33 5.37E-13 0.58 1.13
Interleukin 3 receptor alpha (IL3RA) DTT IL3RA 8.71E-54 0.98 2.64
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04156256) CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of iCell Gene Therapeutics.